Jinyu Bio-tech subsidiary secures new quadruple vaccine approval

Jinyu Bio-technology Co., Ltd. (SSE: 600201) announced that its subsidiary, Liaoning Yikang Bio-Pharmaceutical Co., Ltd., has received approval for a new quadruple inactivated vaccine for poultry. The vaccine targets Newcastle disease, H9 avian influenza, infectious bursal disease, and adenoviral disease (group I, type 4). This "four-in-one" approach simplifies vaccination protocols, reduces costs, and minimizes stress on poultry compared to multiple injections. The vaccine, administered via subcutaneous or intramuscular injection, provides 3 months of immunity in chicks and 6 months in adult chickens. While the new veterinary drug registration certificate has been granted, Liaoning Yikang must still secure product approval numbers before the vaccine can be marketed. This development strengthens Jinyu's poultry vaccine portfolio and reinforces its commitment to research and development.